Why Are There So Few Approved Gene Therapies?

Gene therapy has been called the future of medicine for more than 30 years. Yet as of the mid-2020s, the number of gene therapies approved by the U.S. Food and Drug Administration is still small. The reason is not a lack of scientific interest. It is a mix of biology, manufacturing, cost, and regulation. Each of those barriers is real, and each one is hard to solve.

Gene therapy works by adding, replacing, or editing genetic material inside a patient’s cells. In theory, that could treat thousands of diseases caused by a single faulty gene. In practice, the human body makes this far more difficult than it looks on paper. Delivery is hard. Safety is hard. Making the product at scale is hard. And proving it works in a trial is slow and expensive.

Why Are There So Few Approved Gene Therapies?

The short answer is that gene therapy sits at the intersection of the hardest problems in medicine. You have to get genetic material into the right cells, in the right amount, without triggering a dangerous immune response, and then prove in a clinical trial that this actually changes the course of a disease.

Most approved gene therapies treat rare diseases caused by a single gene. These are the easiest targets. When a disease involves many genes, or when the affected cells are hard to reach, the problem gets much harder. That is why the list of approved products is dominated by a small number of conditions rather than the hundreds of genetic diseases that exist.

Three bottlenecks show up again and again:

• Delivery. Getting the therapy to the right tissue is often the single biggest obstacle.
• Manufacturing. These are not simple pills. They are living biological products made in specialized facilities.
• Evidence. Proving a treatment works and stays safe takes years of trials with very few eligible patients.

What Makes Gene Delivery So Difficult?

Your body has spent millions of years developing defenses against foreign genetic material. That is normally a good thing. It is what protects you from viruses. But it also means the body treats a gene therapy much like it treats an infection.

Most gene therapies use a modified virus as a delivery vehicle, called a vector. The virus is stripped of the parts that cause disease and loaded with a therapeutic gene. The most common vector is adeno-associated virus, or AAV. AAV vectors are used in several approved products. They work well for some tissues but not others.

The challenges are practical:

• AAV vectors tend to concentrate in the liver and some other tissues. Reaching muscle, brain, or specific cell types is harder.
• The immune system can recognize the vector and mount a response, which can reduce how long the therapy works or cause side effects.
• Many people already carry antibodies against common AAV types from prior natural exposure, which can block the therapy before it works.
• There is a size limit. AAV can only carry a relatively small gene, so some diseases simply cannot be targeted this way.

Other approaches exist. Some therapies modify a patient’s cells outside the body and then return them. That is called ex vivo therapy, and it avoids the delivery problem entirely but requires a complex lab process for each patient.

Why Is Manufacturing Gene Therapy So Hard?

A gene therapy is not manufactured the way a conventional drug is. It is a biological product grown in living cells, then purified, tested, and frozen. Every step has to be tightly controlled, and small changes can alter the final product.

Scale is the core problem. A single patient may need a dose measured in the hundreds of trillions of vector particles. Producing that reliably for thousands of patients requires specialized facilities that are expensive to build and slow to expand.

This has real consequences:

• Capacity is limited, so companies cannot always meet demand even after approval.
• Production costs are high, which feeds directly into the price of the therapy.
• Quality testing for each batch is extensive and time-consuming.
• Scaling up a process that worked in small trials does not always produce the same result.

Several approved gene therapies carry list prices in the millions of dollars per patient. That price reflects real costs, but it also limits how widely these treatments can be used and how many companies can afford to develop them.

How Do Clinical Trials Slow Approval?

To approve a therapy, regulators need evidence that it works and that the benefits outweigh the risks. For rare diseases, that evidence is hard to gather.

Many of these conditions affect only a few thousand people worldwide, sometimes fewer. Recruiting enough patients for a trial takes years. Because the diseases are serious and often have no other treatment, researchers sometimes rely on single-arm trials without a placebo group, which can make the results harder to interpret.

Then there is the question of durability. A gene therapy is often designed to work after a single dose. Regulators want to know how long the effect lasts. That means following patients for years, which stretches out the timeline before and after approval.

Safety monitoring does not stop at approval. Because these are relatively new treatments, regulators often require long-term follow-up to watch for delayed effects, including the rare possibility of cancer caused by the therapy inserting itself in the wrong place in the genome.

What Are the Safety Concerns With Gene Therapy?

Gene therapy carries real risks, and the field has learned this the hard way. Early trials in the 1990s saw serious complications, including deaths, which set the field back for years.

Known risks include:

• Immune reactions. The body can attack the vector or the cells carrying it, sometimes severely.
• Insertional mutagenesis. If genetic material lands in the wrong spot, it can disrupt a gene that controls cell growth. This has been linked to leukemia in some early trials using certain vectors.
• Off-target effects. For gene editing approaches, the editing tool can sometimes cut DNA in unintended places.
• Loss of effect over time. Some therapies stop working as targeted cells are replaced or the immune system clears the vector.

These risks are not theoretical. They are why regulators require extensive testing and why some promising therapies have been paused or withdrawn. The balance of risk and benefit is different for a fatal childhood disease than for a condition a patient could live with for decades.

How Does Gene Therapy Compare to Other Treatments?

Gene therapy is not the only way to treat genetic disease. It is one option among several, and it is not always the best one. The table below compares the general categories, not specific products.

For some diseases, enzyme replacement or other treatments remain the standard of care. Gene therapy may offer a one-time option, but it is not automatically better. The comparison depends on the disease, the patient, and how well each option performs in trials.

What Would Need to Change for More Approvals?

More gene therapies are moving through the pipeline. The number of clinical trials has grown substantially over the past decade, and several products are in late-stage testing. But the same barriers keep slowing the pace.

Progress would likely require a combination of things:

• Better delivery systems that reach more tissues with fewer immune problems.
• Cheaper, faster, and more scalable manufacturing.
• New payment models, since a one-time multi-million-dollar treatment does not fit neatly into how insurers and governments usually pay for care.
• Faster trial designs that still produce trustworthy evidence.

None of these is easy. Each one is an active area of research. That is why the field is growing but not exploding. The science is real, but so are the obstacles.